Geode Capital Management LLC Acquires 313,335 Shares of Fractyl Health, Inc. (NASDAQ:GUTS)

Geode Capital Management LLC grew its holdings in shares of Fractyl Health, Inc. (NASDAQ:GUTS) by 166.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 501,476 shares of the company’s stock after buying an additional 313,335 shares during the quarter. Geode Capital Management LLC owned 1.04% of Fractyl Health worth $1,269,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its stake in Fractyl Health by 54.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Fractyl Health by 56.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after purchasing an additional 29,262 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $33,000. Massachusetts Financial Services Co. MA grew its holdings in Fractyl Health by 2.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock worth $4,255,000 after buying an additional 25,829 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Fractyl Health in the 3rd quarter valued at $38,000.

Fractyl Health Price Performance

GUTS opened at $1.90 on Friday. Fractyl Health, Inc. has a 1 year low of $1.74 and a 1 year high of $14.50. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The company has a market capitalization of $91.39 million and a price-to-earnings ratio of -0.16. The firm’s fifty day moving average price is $2.19 and its two-hundred day moving average price is $2.82.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million for the quarter. As a group, analysts anticipate that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Insider Transactions at Fractyl Health

In other news, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99. Following the completion of the sale, the chief executive officer now owns 491,329 shares in the company, valued at $1,213,582.63. This trade represents a 16.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the sale, the insider now directly owns 153,544 shares in the company, valued at $379,253.68. This trade represents a 29.48 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.